Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
Joly
P
P
Department of Dermatology, Hôpital Charles Nicolle, Rouen, France.
Lampert
A
A
Thomine
E
E
Lauret
P
P
D006916:5-Hydroxytryptophan / Q000009:adverse effects*; D000368:Aged; D002230:Carbidopa / Q000009:adverse effects*; D002908:Chronic Disease; D003863:Depression / Q000188:drug therapy; D004359:Drug Therapy, Combination; D016603:Eosinophilia-Myalgia Syndrome / Q000139:chemically induced; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy; D012594:Scleroderma, Localized / Q000139:chemically induced*
D006916:5-Hydroxytryptophan; D002230:Carbidopa